» Articles » PMID: 34127048

Serum Uric Acid, Disease Severity and Outcomes in COVID-19

Overview
Journal Crit Care
Specialty Critical Care
Date 2021 Jun 15
PMID 34127048
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The severity of coronavirus disease 2019 (COVID-19) is highly variable between individuals, ranging from asymptomatic infection to critical disease with acute respiratory distress syndrome requiring mechanical ventilation. Such variability stresses the need for novel biomarkers associated with disease outcome. As SARS-CoV-2 infection causes a kidney proximal tubule dysfunction with urinary loss of uric acid, we hypothesized that low serum levels of uric acid (hypouricemia) may be associated with severity and outcome of COVID-19.

Methods: In a retrospective study using two independent cohorts, we investigated and validated the prevalence, kinetics and clinical correlates of hypouricemia among patients hospitalized with COVID-19 to a large academic hospital in Brussels, Belgium. Survival analyses using Cox regression and a competing risk approach assessed the time to mechanical ventilation and/or death. Confocal microscopy assessed the expression of urate transporter URAT1 in kidney proximal tubule cells from patients who died from COVID-19.

Results: The discovery and validation cohorts included 192 and 325 patients hospitalized with COVID-19, respectively. Out of the 517 patients, 274 (53%) had severe and 92 (18%) critical COVID-19. In both cohorts, the prevalence of hypouricemia increased from 6% upon admission to 20% within the first days of hospitalization for COVID-19, contrasting with a very rare occurrence (< 1%) before hospitalization for COVID-19. During a median (interquartile range) follow-up of 148 days (50-168), 61 (12%) patients required mechanical ventilation and 93 (18%) died. In both cohorts considered separately and in pooled analyses, low serum levels of uric acid were strongly associated with disease severity (linear trend, P < 0.001) and with progression to death and respiratory failure requiring mechanical ventilation in Cox (adjusted hazard ratio 5.3, 95% confidence interval 3.6-7.8, P < 0.001) or competing risks (adjusted hazard ratio 20.8, 95% confidence interval 10.4-41.4, P < 0.001) models. At the structural level, kidneys from patients with COVID-19 showed a major reduction in urate transporter URAT1 expression in the brush border of proximal tubules.

Conclusions: Among patients with COVID-19 requiring hospitalization, low serum levels of uric acid are common and associate with disease severity and with progression to respiratory failure requiring invasive mechanical ventilation.

Citing Articles

Severe acute respiratory syndrome coronavirus 2 infection unevenly impacts metabolism in the coronal periphery of the lungs.

Laro J, Xue B, Zheng J, Ness M, Perlman S, McCall L iScience. 2025; 28(2):111727.

PMID: 39995861 PMC: 11848469. DOI: 10.1016/j.isci.2024.111727.


Downregulation of type I interferon signalling pathway by urate in primary human PBMCs.

Badii M, Nica V, Straton A, Kischkel B, Gaal O, Cabau G Immunology. 2024; 174(1):100-112.

PMID: 39354748 PMC: 11652411. DOI: 10.1111/imm.13858.


The predictive significance of uric acid to high density lipoprotein- cholesterol ratio and uric acid for the severity and mortality of coronavirus disease-19.

Rohani-Rasaf M, Ghavidel F, Hosseini H, Teimouri M BMC Res Notes. 2024; 17(1):277.

PMID: 39334249 PMC: 11437878. DOI: 10.1186/s13104-024-06807-7.


Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters.

Rajaiah R, Pandey K, Acharya A, Ambikan A, Kumar N, Guda R iScience. 2024; 27(8):110501.

PMID: 39171289 PMC: 11338146. DOI: 10.1016/j.isci.2024.110501.


Exploring the Relationship of SARS-CoV-2 and Uric Acid Levels With a Focus on Gout Patients: A Scoping Review.

Patel H, Basra M, Muralidhar R, Demory Beckler M, Kesselman M Cureus. 2024; 16(3):e57138.

PMID: 38686242 PMC: 11057641. DOI: 10.7759/cureus.57138.


References
1.
Bairaktari E, Kakafika A, Pritsivelis N, Hatzidimou K, Tsianos E, Seferiadis K . Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis. 2003; 41(6):1225-32. DOI: 10.1016/s0272-6386(03)00355-x. View

2.
Wakasugi M, Kazama J, Narita I, Konta T, Fujimoto S, Iseki K . Association between hypouricemia and reduced kidney function: a cross-sectional population-based study in Japan. Am J Nephrol. 2015; 41(2):138-46. DOI: 10.1159/000381106. View

3.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

4.
He B, Wang J, Wang Y, Zhao J, Huang J, Tian Y . The Metabolic Changes and Immune Profiles in Patients With COVID-19. Front Immunol. 2020; 11:2075. PMC: 7485144. DOI: 10.3389/fimmu.2020.02075. View

5.
Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G . Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med. 2020; 8(12):1201-1208. PMC: 7834127. DOI: 10.1016/S2213-2600(20)30370-2. View